Sirolimus-Eluting Versus Bare-Metal Low-Profile Stent for Renal Artery Treatment (GREAT Trial): Angiographic Follow-up After 6 Months and Clinical Outcome up to 2 years

Zähringer, M.; Sapoval, Marc; Pattynama, Peter M. T.; Rabbia, C; Vignali, C; Maleux, Geert; Boyer, L.; Szczerbo-Trojanowska, Małgorzata; Jaschke, Werner; Hafsahl, Geir; Downes, Mark; Beregi, Jean‐Paul; Veeger, Nic; Stoll, Hans‐Peter; Talen, Aly

doi:10.1583/1545-1550(2007)14[460:svblsf]2.0.co;2

Cited by 49 publications

(33 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The United States multicenter trial found no beneficial effect of 3-month warfarin treatment after the procedure. 23 Four comparative studies showed no improvement in restenosis rate and clinical outcome with gold-, carbon-or sirolimus-coated stents [19][20][21][22] (Table III).…”

Section: Benefit Of Renal Artery Stenting Over Angioplastymentioning

confidence: 99%

Primary stenting for atherosclerotic renal artery stenosis

Steichen

Amar

Plouin

2010

Journal of Vascular Surgery

View full text Add to dashboard Cite

show abstract

Section: Benefit Of Renal Artery Stenting Over Angioplastymentioning

confidence: 99%

Primary stenting for atherosclerotic renal artery stenosis

Steichen

Amar

Plouin

2010

Journal of Vascular Surgery

View full text Add to dashboard Cite

show abstract

“…Mit schwerwiegenderen prozedurbedingten Komplikationen wie akutem Nierenversagen, Niereninfarkt, perirenalem Hämatom und thrombotischem Nierenarterienverschluss muss in 9% der Fälle gerechnet werden [28]. Keine Vorteile scheinen hingegen beschichtete Stents im Vergleich zu unbeschichteten Stents zu haben [53].…”

Section: Interventionelle Therapieunclassified

Die Nierenarterienstenose

et al. 2009

View full text Add to dashboard Cite

Renal artery stenosis (RAS) is both a common and progressive disease and its prevalence in patients > 65 years is 6.8%. In patients with known or suspected atherosclerosis undergoing coronary angiography, a frequency of even 11-23% is reported in the literature. Despite this high prevalence, there is an ongoing discussion about the indications for revascularization and it is currently unclear, whether renal artery revascularization reduces adverse cardiovascular and renal events. Nevertheless, the number of interventions for RAS is rising steadily, although up to 40% of patients do not profit from this intervention. This fact underlines the necessity of a thorough diagnostic work-up before intervention, integrating morphological and functional tests. For morphological evaluation, multislice computed tomography, magnetic resonance tomography or digital subtraction angiography can be done. In experienced centers, Doppler ultrasound can serve as an excellent functional tool, to assess the physiological relevance of an RAS, but also invasive measurements of pressure and flow provide valuable information about the significance of stenoses; however, these methods will have to be assessed with respect to their value to predict long-term outcome. Although percutaneous intervention of RAS is associated with a substantially lower risk of major adverse events as compared to surgery, by using contrast media this procedure holds the risk of deterioration of renal function and of a small number of procedure-dependent complications as well. Thus, a careful consideration of pros and cons of this procedure is mandatory.

show abstract

“…Im Rahmen der GRE ATStudie wurde der Effekt von mit Si rolimus beschichteten Stents prospektiv, nicht randomisiert, nichtgeblindet und multizentrisch untersucht. Nach 6 Mona ten konnte weder in Bezug auf die Offen heitsrate, noch in Bezug auf den Blutdru ckeffekt ein signifikanter Unterschied zu nicht beschichteten Stents festgestellt wer den [76].…”

Section: Beschichtete Stentsunclassified

Hypertonie bei Patienten mit Nierenarterienstenosen

Voiculescu

Rump

2008

Internist

View full text Add to dashboard Cite

Renal artery stenosis (RAS) is often present in patients with severe hypertension and atherosclerotic vascular disease. In this setting it is important to screen patients for renovascular disease, e.g. with Duplex-ultrasound, CT- or MR-angiography. The challenge of treating these patients is to find the evidence proving that the RAS is responsible for hypertension and/or renal dysfunction. Measurement of the intra-arterial pressure gradient is necessary in order to determine hemodynamic relevance. On the other side, in these patients hypertension is often of primary and/or renoparenchymatous origin and is aggravated by a renovascular disease. This explains why hypertension cannot be cured even if a high grade stenosis has been removed. In addition, thromb- and cholesterol-embolic material is often mobilized during an invasive procedure and leads to renaparenchymatous ischemia which sustains hypertension after intervention. An individual evaluation of profit versus risk is important for the decision for or against an invasive procedure, especially since there is no sufficient evidence for a decrease of mortality after interventions of RAS. The optimal conservative treatment, including the treatment of atherosclerotic risk factors is recommended.

show abstract

Sirolimus-Eluting Versus Bare-Metal Low-Profile Stent for Renal Artery Treatment (GREAT Trial): Angiographic Follow-up After 6 Months and Clinical Outcome up to 2 years

Cited by 49 publications

References 17 publications

Primary stenting for atherosclerotic renal artery stenosis

Primary stenting for atherosclerotic renal artery stenosis

Die Nierenarterienstenose

Hypertonie bei Patienten mit Nierenarterienstenosen

Contact Info

Product

Resources

About